Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regulus Therapeutics, a biopharmaceutical company, has initiated a new discovery in microRNA therapeutics for the treatment of glioblastoma multiforme (GBM), a form of brain tumor in humans.
Subscribe to our email newsletter
microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression.
Regulus’ expertise in microRNA therapeutics will be used to discover chemically modified oligonucleotide anti-miRs.
Regulus Therapeutics chief scientific officer Neil W Gibson said GBM is a hazardous disease whose treatment options are very limited.
"At Regulus, we have successfully targeted microRNAs in multiple disease settings and believe that targeting dysregulated microRNAs using chemically modified oligonucleotide anti-miRs provides a potential therapeutic approach for GBM," Gibson added.